What is the safest skeletal muscle relaxant to use in a patient with an implanted defibrillator (implantable cardioverter-defibrillator, ICD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safest Skeletal Muscle Relaxant in Patients with Implanted Defibrillators

Rocuronium is the safest skeletal muscle relaxant for patients with implanted cardioverter-defibrillators (ICDs), as it is a non-depolarizing agent that does not interfere with device sensing or defibrillation thresholds and can be reliably reversed with sugammadex. 1

Why Rocuronium is the Preferred Agent

Rocuronium does not affect ICD sensing algorithms or defibrillation thresholds, making it the optimal choice when neuromuscular blockade is required in this population 1. The drug provides rapid onset (60-90 seconds with 0.6 mg/kg dosing) and intermediate duration of action, allowing for controlled anesthesia without prolonged paralysis 1.

Critical: Avoid Depolarizing Agents

Succinylcholine must be avoided despite its rapid onset, as depolarizing agents can theoretically interfere with ICD sensing algorithms and cause muscle fasciculations that may be misinterpreted by the device 1. The risk-benefit ratio strongly favors non-depolarizing agents in ICD patients, even when rapid sequence intubation is required 1.

Dosing Strategy

  • Standard intubating dose is 0.6 mg/kg (2 x ED95), providing good to excellent intubating conditions within 60-90 seconds 1
  • Calculate dose based on lean body weight in obese patients rather than actual body weight 1

Reversal Protocol is Mandatory

Sugammadex provides reliable reversal and is essential for safe use of rocuronium in this population 1:

  • 2.0 mg/kg for moderate blockade 1
  • 4.0 mg/kg for deep blockade 1
  • 8.0 mg/kg for very deep blockade 1

Neuromuscular monitoring must be used to determine the depth of blockade and appropriate sugammadex dose, as well as to identify potential recurarization 1. Reversal efficacy may be decreased in elderly patients and those with severe renal failure (creatinine clearance <30 mL/min), requiring careful monitoring in these populations 1.

ICD-Specific Precautions During the Procedure

The ICD should be interrogated before and after any procedure requiring anesthesia to ensure appropriate function, as external electrical interference or drug effects could alter programmed parameters 2, 1. This is standard practice for all patients with implanted cardiac devices undergoing procedures 2.

If cardioversion is required during the procedure, paddles should be positioned in anterior-posterior configuration to minimize risk to the ICD generator 2, 1. The anterior-posterior electrode configuration reduces the risk of exit block compared to positioning one paddle near the impulse generator and the other over the cardiac apex 2.

Common Pitfalls to Avoid

  • Do not position defibrillation pads directly over the ICD generator if emergency cardioversion becomes necessary, as this increases risk of device malfunction 1
  • Do not rely on clinical assessment alone for reversal adequacy—objective neuromuscular monitoring is mandatory to prevent residual blockade 1
  • Gloves should be worn by healthcare providers coming into contact with patients during potential device discharge to limit risk of electrification 3
  • A ring magnet must be available to inactivate the ICD unit if necessary during the procedure 3

Alternative Muscle Relaxants Are Not Recommended

While other skeletal muscle relaxants like cyclobenzaprine, carisoprodol, and tizanidine are used for musculoskeletal conditions 4, 5, these oral agents are not appropriate for procedural neuromuscular blockade and lack the specific safety profile established for rocuronium in ICD patients 1. The evidence supporting rocuronium's safety in this population is based on its lack of interference with device function, which has not been established for other agents 1.

References

Guideline

Safest Muscle Relaxant in Patients with Implanted Defibrillators

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Anesthesia and implantable automatic defibrillator].

Annales francaises d'anesthesie et de reanimation, 1996

Research

Skeletal muscle relaxants.

Pharmacotherapy, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.